Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He has not heard $hitttt… Hahahahaha, he cant even make a point right…. Other than, claiming grammar errors, of course… I gotta stop typing while on the road… Smh…
Anyways, someone bought $200 worth of shares and brought it to $0.0003… If it comes down back again to $0.0001 it is just MMs playing games. This will take a while. If HMBL has pulled off after all these years, certainly Otiko may… Well, assuming Otiko’s CPA is as competent as Foote’s …. Con-Air
You do realize that 685K volume is like $200 and exchange at 0.0003, right… Assuming an international buyer is getting it. Lmao… Smh… Nobody knows anything
685k in volume today? Most we've seen in a few weeks. Think we might be getting some news very soon it seems. It looks like somebody knows something and trying load up on some cheapies.
Please enlighten us with what you heard?
Posted using English words, but makes zero sense! Relax, all will be well!
Heard EXACTLY what I wanted to hear, lately! Nothing inside, but informing!
The D-As selling right now are getting nothing! RELAX!
It is all out there, make the math from the date the hiring occurred and the date IR was speaking about the filling mess Otiko been doing the time frame gap was very obvious. Easy determination
Well, in his defense, the fillings mistakes occurred way before he considered to hire someone… So, despite he hired someone that knows how to run a company, wouldn’t be capable to shield Viaderma from a mess spread several months ago in just a few days. This would require full reset from the moment fillings mistake were done. It takes time
Otiko hired a bunch of new people but didn't add someone that knows how to actually run the company. He's a complete idiot when it comes to running a business.
Maybe 100 mill bottles of staining snake oil
What's to go after his millions .0001 shares?
The Dr. has his a$$ & assets covered trust me
Good question. You would think she would have been able to have the filings completed a long time ago, but she might be hesitant about risking her own reputation and potential legal troubles if what the company is reporting, or not reporting, is inaccurate, missing proof of sales revenues or for other required information for compliance purposes.
The longer this takes for them to file, the worse it looks. Might need to start talking to your attorneys because if the revenue numbers aren't included in the new filings, then all the previous PRs were fraudulent and there will be no getting out of this one. There's a lot of law firms that would take this class action lawsuit on too.
Hopefully that's not the case and there's nothing fraudulent going on, but it's not looking too great right now.
All I want to know is HOW MUCHNIS CPA ZIA CHOE receiving??? She should be able to file the report correctly as long as Otiko is providing her with accurate information!!! Sort of soils Zia's reputation in my opinion!!!!!
Upon actual completion of overdue Annual Report, otiko has to go through entire listing process again to re-list. That could be extended due to finding a willing market maker and the government bureaucracy itself, even more so if someone actually reads the reports, and requires them to be complete and accurate presentations, and not the D- efforts of the past.
https://www.securitieslawyer101.com/2022/otc-markets-expert-market/
You remember IR saying Otiko to have filed in the past, wrongful files with mistakes it. This is difficult to undo. I imagine the workload and manpower that needs to take in order to correct straight, all from the beginning. Ouch! Once it is done, Audited, it can move forward: otcqb
They've had well over 6 months to get this all completed. I'd imagine several lawsuits against the company will be initiated soon and very likely a class action lawsuit too.
Something is smelling "VERY FISHY".... Dr/CEO has IR send PR stating they are working through having the annual and Quarterly filed. Not sure why that would be taking sooo long.
You speak like you did sell before it went Expert Market
He fooled all investors
He fooled all investors
Is otiko alive?
Is otiko alive?
The good Dr. Needs to sell some of that to Iran their going to need it.
Gross negligence is not like a first time mistake
Gross negligence...definitely yes. Fraud? For all of our sakes, I sure hope not.
I'd be extremely happy to see the company sold and Otiko thrown in prison for the fraud that he is.
EnigmaticVolcano64You most likely know as much as we do.
Beyond disappointed in continued negligence and incompetence. Is there any chance the doc 1) receive an offer for buyout and 2) would entertain it?
For some of you guys that have been around more than I have (3 years) have you caught wind of any offers? The Company is crap but the product is legit. I would think that would attract a buyer—especially in this season of sitting in timeout.
Scam capitals of the world Nigeria & British Vancouver
All of this was well planed don't kid yourself
The FEDS may have spanked the Dr. good this time
I agree, if your average is low enough. We all might be able to get out with our original investment. If it gets that high again. Let's see profit to "0" back to profit. Hell gotta stay to the end then. Lol
Naah. I don’t think this is the case. The doc really screwed up but he will fix it
What do you mean? It is in Expert Market mate! Nothing is going!! Chuckles
I am sure you are far from alone in the loss volume. I personally well past 6 figures. Not happy at all but not my first loss and way offset by a few of my tremendous wins.. that is the nature of this playing with pennies. If at previous price you were all in, SHAME ON YOU.
Absolute Failure as a CEO of his Fidicuary Duty to Shareholders!!!
If you have what I have showing as a loss from this Scumbag Dr, then come talk to me! Until then, no need to reply to me. Beyond livid with both of them since they have no regard for the shareholders. Just look at how he thinks when Rich has said to people in emails when questioning the cancelling of the company loan to Dr Otiko when he was starting Wound Pros which he then denied- "Oh well the Dr has invested a lot of his own money and deserves to write off the $300k company loan to himself"!!!!
Do you really have time to post such bull sh,,
Rich and Dr probably packing up and getting ready to high tail it out of the country and to one of their choosing before possibly getting indicted if funny business happened.
Months past due on 2024 filings and Q1 2025 too. The company recently claimed they are fully operational and filings should be done soon for regulatory compliance.
https://www.otcmarkets.com/stock/VDRM/news/ViaDerma-Inc-Confirms-Ongoing-Operations-and-Commitment-to-Regulatory-Compliance
TBD on the timeline though.
Extremely frustrating for all and this cannot happen again. If it does, .0001 will be the new high for a very long time.
Company contacts if you need answers.
info@viaderma.com
ir@viaderma.com
richardinza@gmail.com
What the heck is happening to this stock?
Thanks for the feedback Gameccks1
Followers
|
630
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
76578
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |